BC Week In Review | Sep 12, 2011
Clinical News

Olaparib: Phase I started

Cancer Research U.K. (London, U.K.) began an open-label, dose-escalation, U.K. Phase I trial to evaluate AstraZeneca's oral olaparib in combination with temozolomide in patients with relapsed GBM that requires surgery. In the first part of...
BC Week In Review | Jun 6, 2011
Clinical News

ALN-VSP: Additional Phase I data

Additional data from 27 evaluable patients in an open-label, dose-escalation Phase I trial showed that IV ALN-VSP every 2 weeks produced 1 partial response and 7 cases of stable disease. The trial, which enrolled 41...
BC Week In Review | Apr 4, 2011
Clinical News

ALN-VSP: Completed Phase I enrollment

Alnylam completed enrollment of over 40 patients in an open-label, dose-escalation Phase I trial evaluating 0.1-1.5 mg/kg IV ALN-VSP. The company developed ALN-VSP using Tekmira's stable nucleic acid-lipid particles (SNALP) technology. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY),...
BC Week In Review | Jan 10, 2011
Clinical News

ALN-VSP: Interim Phase I data

Interim data from tumor biopsies from 8 patients in an open-label, dose-escalation Phase I trial showed that 0.4-1.25 mg/kg IV ALN-VSP produced ALN-VSP concentrations of 0.3-142 ng/g tissue, which Alnylam said was "pharmacologically relevant." Additionally,...
BC Week In Review | Jun 7, 2010
Clinical News

ALN-VSP: Interim Phase I data

Interim data from 12 evaluable patients in an open-label, dose-escalation Phase I trial showed that 0.1-0.4 mg/kg IV ALN-VSP every 2 weeks was well tolerated with no signs of hepatotoxicity. At the 0.7 mg/kg dose,...
BC Week In Review | May 24, 2010
Clinical News

RG7334: Phase I start

Roche began an open-label, dose-ranging, European Phase I imaging trial to evaluate intravenous RG7334 in up to 50 patients. The start triggers a €10 million ($12.3 million) milestone payment to ThromboGenics and BioInvent, which will...
BC Week In Review | Jun 8, 2009
Clinical News

BNC105: Interim Phase I data

Interim data from 9 patients with advanced solid tumors in an Australian Phase I trial showed that 2.1-18.9 mg/m 2 IV BNC105 resulted in 2 cases of stable disease. At doses >= 8.4 mg/m 2,...
BC Week In Review | May 18, 2009
Clinical News

Arenegyr: Phase I started

MolMed began an open-label, dose-escalation, Italian Phase I trial (NGR013) to evaluate 60, 80, 100 and 120 µg/m 2 of IV NGR-hTNF given once every 3 weeks for 4 treatment cycles in 16 patients. MolMed...
BC Week In Review | Apr 13, 2009
Clinical News

ALN-VSP: Phase I started

Alnylam began an open-label, U.S. Phase I trial to evaluate intravenous ALN-VSP in about 55 patients. The company developed ALN-VSP using Tekmira's stable nucleic acid-lipid particles (SNALP) technology. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass.  ...
BC Week In Review | Feb 9, 2009
Clinical News

Pieris preclinical data

In mouse xenograft models of cancer, PRS-050 produced a complete inhibition of tumor growth. In rat xenograft models of colon cancer, the anticalin targeting vascular endothelial growth factor (VEGF) demonstrated a significant decrease in tumor...
Items per page:
1 - 10 of 10